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Since the early 1990s, with significant improvement in the procedural success of percutaneous
coronary interventions (PCIs), there has been a concomitant reduction in the need for
emergency coronary artery bypass graft surgery. This review article focuses on the need for
on-site cardiac surgery in patients with acute myocardial infarction undergoing primary
angioplasty at centers without on-site cardiac surgical backup. It gives an overview of the need
for emergency bypass surgery in both the large trial setting and the community hospital
setting. Special consideration is also given to the risks and benefits of primary angioplasty
compared with thrombolytic therapy, transfer to an institution with an on-site cardiac surgical
facility compared with primary PCI, the frequency and indications for emergency cardiac
surgery related and unrelated to primary angioplasty and the requirements for primary
angioplasty that must be met in hospitals without the capability of on-site cardiac
surgery. (J Am Coll Cardiol 2002;39:1881–9) © 2002 by the American College of
Cardiology Foundation
The initial experience with percutaneous coronary interven-
tion (PCI) was characterized by complications, including
coronary dissection, acute recoil, coronary perforation and
coronary thrombosis (1). The immediate remedy for many
of these complications was emergency coronary artery by-
pass graft surgery (CABG), and the performance of PCI
was predicated on the availability of on-site cardiac surgery.
The joint guidelines of the American College of Cardiology
and the American Heart Association (ACC/AHA), pub-
lished in 1996 and updated in 1999, stated that primary PCI
in patients with acute myocardial infarction (AMI) who are
eligible for thrombolysis should not be performed by a
low-volume operator in a laboratory without surgical capa-
bility (class III indication) (2,3). In the British Cardiac
Society Guidelines, of 20,511 PCI procedures performed in
the U.K. in 1996, 1,382 (7%) were performed in six centers
without on-site cardiac surgical capabilities (4). Emergency
CABG within 24 h was required in 1.5% of patients.
Surgical backup, whether on-site or off-site, was recom-
mended for all coronary angioplasty procedures (4). In
Canada, the Cardiac Care Network of Ontario (5) recently
recommended to the Ontario Ministry of Health that pilot
programs be set up in Ontario to perform coronary angio-
plasty (both primary and elective) at hospitals without
on-site surgical backup.
The 2001 ACC/AHA guidelines recommend that pri-
mary PCI for patients with AMI (defined as ongoing chest
pain and ST-segment elevation or new left bundle branch
block on the electrocardiogram [ECG]) at hospitals without
on-site cardiac surgery be restricted to institutions that can
meet the following standards: 1) more than 36 cases of
primary PCI performed annually; 2) a proven plan for rapid
access to a nearby surgical facility; 3) PCI that can be
performed rapidly (balloon inflation within 90  30 min);
and 4) skilled operators at the institution who regularly
perform at least 75 PCI procedures per year (6). If those
prerequisites can be met, PCI without on-site cardiac
surgery is regarded as a class IIb indication (the weight of
the evidence does not favor performance of the procedure).
The continued concerns about performing PCI for patients
with AMI without surgical capabilities on-site, as well as
the reason it is listed as a class IIb indication, rather than
class IIa or class I, relate to patients who may require
immediate cardiac surgery after PCI.
Since the early 1980s, the PCI technique, equipment and
outcomes have improved significantly (7,8). Since the early
1990s, with improvements in procedural success, there has
been a concomitant reduction in complications, especially in
the need for emergency CABG (8,9). Selection criteria for
patients and lesions have broadened to include high-risk
patients, including those who are elderly, those with non–
ST-segment elevation coronary syndromes and those in
cardiogenic shock (7–11).
In light of this progress, it is the opportune time to
re-evaluate the necessity of having an on-site cardiac surgi-
cal capability at institutions where PCI is performed in
patients with AMI. This review focuses on this need for
patients with evolving AMI. In this setting, primary PCI
has the greatest potential to reduce mortality, salvage the
myocardium and avoid delays incurred by transferring pa-
tients to a cardiac surgical facility.
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Emergency CABG after primary PCI for patients with
AMI. In randomized, controlled trials, the reported rate of
emergency CABG for failed primary PCI is low (12–18)
(Table 1). In the Primary Angioplasty in Myocardial
Infarction-2 (PAMI-2) trial, primary PCI was performed in
982 patients (18). Of these patients, 67 (6.8%) underwent
cardiac surgery during the index hospital admission for
severe triple-vessel disease or left main coronary artery
disease. Only four patients (0.4%) required emergency
surgery for a complication resulting from failed PCI. The
PAMI-2 investigators concluded that a distinction needs to
be made between urgent CABG performed on the basis of
“high-risk” coronary anatomic features and true emergency
CABG performed after failed PCI. Moreover, the rate of
emergency CABG may be higher when the procedure is
available on-site (19,20). Based on the low rate of emer-
gency CABG, the PAMI-2 investigators recommended
that primary PCI be performed without on-site cardiac
surgical capabilities if a protocol exists for the rapid transfer
of the patient to a nearby facility with on-site cardiac
surgical capabilities. In our review of the combined experi-
ence of six major randomized trials comparing primary PCI
with thrombolytic therapy, we found that only 6 (0.31%) of
1,953 patients required emergency CABG for failed PCI
(Table 1).
Although the risk of an angioplasty-related complication
requiring CABG is low, the following points need to be
considered when contemplating primary PCI without on-
site cardiac surgical capabilities:
1) the risks and benefits of primary PCI versus thrombo-
lytic therapy;
2) the risks and benefits of primary PCI versus transfer of
patients to an institution with on-site cardiac surgical
capabilities for those not eligible for thrombolytic therapy;
3) the outcome for patients who are treated with the
intention that they will receive primary angioplasty, but
who do not receive it;
4) the frequency of and indications for emergency CABG
unrelated to PCI complications;
5) the management of PCI complications that may be
alleviated by emergency CABG;
6) the requirements that must be met in hospitals without
on-site cardiac surgical capabilities to perform primary
PCI safely and effectively.
PCI versus thrombolytic therapy. Randomized studies
have demonstrated the safety and efficacy of primary angio-
plasty for the treatment of AMI in patients eligible for
thrombolytic therapy (21–23). A meta-analysis of 2,606
patients enrolled in these trials suggested that primary
angioplasty reduces mortality, stroke and recurrent isch-
emia, as compared with thrombolytic therapy (24). The risk
of death was 4.4% for patients treated with primary PCI and
6.5% for patients treated with thrombolysis, which repre-
sents 21 lives saved per 1,000 patients treated. The rates of
death or nonfatal MI were 7.2% for primary PCI and 11.2%
for thrombolytic therapy (40 fewer events per 1,000 patients
treated). Pooled data show that the reduction in mortality
persists for at least six months. In the Netherlands trial, the
mortality benefit favoring primary PCI has persisted for
more than three years (25). In one small study in which 71
patients were randomly assigned to receive therapy with a
stent and abciximab, and 69 patients to receive therapy with
alteplase, the median size of the infarct, as measured by
serial scintigraphic studies with technetium-99m sestamibi,
was significantly smaller in patients treated with PCI than
in those treated with thrombolytic medication (26). Despite
the small number of patients, the frequencies of death,
reinfarction and stroke were significantly lower in patients
assigned to receive therapy with stents and abciximab (8.5%)
than in those assigned to receive therapy with alteplase
(23.2%) (p  0.02). Primary angioplasty consistently yields
higher patency rates in the infarct-related artery at 60 and
90 min, less residual stenoses and lower re-occlusion rates
(21,22).
The results of observational registries that may better
Abbreviations and Acronyms
ACC/AHA  American College of
Cardiology/American Heart Association
AMI  acute myocardial infarction
CABG  coronary artery bypass graft surgery
CI  confidence interval
GUSTO  Global Use of Strategies To Open
occluded arteries trial
MITI  Myocardial Infarction Triage and
Intervention registry
MITRA  Maximal Individual TheRapy in Acute
myocardial infarction registry
NRMI  National Registry of Myocardial Infarction
PAMI-2  Primary Angioplasty in Myocardial
Infarction-2 trial
PCI  percutaneous coronary intervention
RR  relative risk
TIMI  Thrombolysis In Myocardial Infarction
trial
Table 1. Randomized Trials of Primary Stenting Versus Balloon
Angioplasty for Acute Myocardial Infarction: Incidence of
Emergency CABG for Failed PCI
Study (Reference) n Design
Emergency CABG
for Failed PCI
PAMI-STENT (12) 900 Multicenter 4 (0.4%)
Suryapranata et al. (13) 452 Single-center 1 (0.2%)
FRESCO (14) 150 Single-center 0
GRAMI (15) 104 Multicenter 1 (1%)
PASTA (16) 136 Multicenter 0
STENTIM-2 (17) 211 Multicenter 0
Total 1,953 6 (0.31%)
Data are presented as the number (%) of patients.
CABG coronary artery bypass graft surgery; FRESCO Florence Randomized
Elective Stenting in acute Coronary Occlusions; GRAMI  Gianturco-Roubin in
Acute Myocardial Infarction; PAMI-STENT  Stent Primary Angioplasty in
Myocardial Infarction; PASTA  Primary Angioplasty versus STent implantation in
Acute myocardial infarction; PCI  percutaneous coronary intervention;
STENTIM-2  Stenting In acute Myocardial Infarction-2.
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reflect the experience of community hospitals do not con-
sistently support the results of the randomized trials favor-
ing PCI over thrombolytic therapy. In the Myocardial
Infarction, Triage and Intervention (MITI) registry, the
outcomes of 1,050 patients who underwent primary PCI
were compared with those of 2,095 patients with ST-
segment elevation MI who received thrombolytic therapy
within 6 h of admission (27). There was no difference in
either in-hospital or long-term mortality during the three-
year follow-up. Moreover, the rates of subsequent proce-
dures and costs were lower among patients in the throm-
bolytic therapy group (27). The second National Registry of
Myocardial Infarction (NRMI) analyzed more than 28,000
patients eligible for thrombolytic therapy within 12 h of
symptoms, who were treated with either intravenous tissue
plasminogen activator or primary PCI (n  4,052). In-
hospital mortality was not statistically different between the
two groups (5.2% vs. 5.4%) (28). Similar findings were
reported from a large European registry (29).
In contrast to the results of these large registries, analysis
of pooled data from the first, second and third NRMIs
showed a greater reduction in early mortality among pa-
tients treated with PCI than among those treated with
thrombolysis (30). In the Cooperative Cardiovascular
Project, a retrospective study of 80,356 elderly North
American Medicare beneficiaries who presented with AMI,
those undergoing primary PCI versus thrombolytic therapy
had lower 30-day mortality (8.7% vs. 11.9%, p 0.001) and
lower one-year mortality (14.4% vs. 17.6%, p 0.001) (31).
In two German registries—the Maximal Individual
TheRapy in Acute myocardial infarction (MITRA) registry
and the Myocardial Infarction Registry—the in-hospital
mortality rate among patients undergoing primary PCI
decreased from 13.9% in 1994 to 3.8% in 1998, whereas
mortality remained unchanged for patients treated with lytic
agents (10.2% in 1994 and 12.7% in 1998) (32). A recent
report from these two registries, which reflect current
clinical practice in Germany, demonstrated that primary
PCI in patients with AMI who were eligible for thrombol-
ysis was associated with lower hospital mortality than in
those who received thrombolytic therapy (33).
The observational results from registries are flawed in
that they can never be risk-adjusted: low-risk patients who
do well clinically may be more likely to receive thrombolytic
therapy, and higher risk patients or those experiencing
clinical deterioration or bleeding risks may be more likely to
be referred for percutaneous interventions. It should also be
noted that the data in some of the older registries, such as
MITI, were most likely collected up to 1995, and the
MITRA registry and the Myocardial Infarction Registry
included more recent outcomes from 1994 to 1998. These
more recent registries showed a steady improvement in the
outcomes of PCI, but not thrombolytic therapy. Thus,
because the outcomes of PCI are steadily improving, data
from older registries are less relevant. Although the results
of the observational studies vary, overall they support the
claim of superiority of primary PCI over thrombolytic
therapy.
The superior outcome associated with primary PCI has
stimulated interest in expanding its availability to hospitals
without on-site cardiac surgery. The paramount question is
how to translate the results of large, randomized, controlled
trials and observational studies in which primary PCI was
almost uniformly performed at centers with on-site cardiac
surgery to community hospitals without on-site cardiac
surgery.
PCI versus transfer for PCI for patients who have
contraindications to therapy with thrombolysis. For pa-
tients with AMI, pre-hospital triage to chest pain centers
allows the reperfusion intervention to be delivered at the
time of the initial presentation. Only about one-third of
patients presenting with AMI are eligible for thrombolytic
therapy (34). Recent data from the NRMI indicate that this
remains true today, even with heightened awareness of the
benefits of reperfusion therapy and a general lessening of
restrictions of or contraindications to thrombolytic treat-
ment (34). However, patients with ongoing chest pain in
the absence of ST-segment elevation, patients with ST-
segment elevation and an increased risk of bleeding (e.g.,
recent stroke) and patients with a nondiagnostic ECG,
advanced age, cardiogenic shock, late presentation or pre-
vious CABG or thrombolytic failure are not eligible to
receive thrombolytic therapy. These patients benefit from
immediate angioplasty (35). Patients with contraindications
to thrombolytic therapy have increased rates of mortality,
reinfarction, stroke and heart failure (35). The results from
the same registry (MITRA) demonstrated a benefit of
primary angioplasty in all subgroups of patients, and as the
mortality from AMI increased, the absolute benefit of
primary angioplasty also increased (33). Offering primary
PCI at the time of the initial presentation, rather than
transferring patients, is especially important for patients in
cardiogenic shock. In the Should We Emergently Revascu-
larize Occluded Coronaries for Cardiogenic Shock trial,
revascularization within 6 h conferred the best survival
advantage of all the descriptors (36).
Patients ineligible to receive thrombolytic therapy should
be transferred to a facility where immediate coronary an-
giography and PCI can be performed, if indicated. How-
ever, the delay involved in transporting a patient to another
facility increases the risk of adverse outcomes (37,38). In the
second NRMI, patients transferred to a tertiary-care center
for primary PCI had the procedure 2.3 h later than those
who arrived at the tertiary-care center directly. The mortal-
ity rate in patients who were transferred was 7.7%, whereas
the mortality rate in patients who were not transferred was
5.0% (p  0.0001) (39). Other studies confirm a relation-
ship between transporting patients to tertiary-care centers
and an increased number of adverse cardiac events, which
are believed to be the result of reduced myocardial salvage
(40).
Several small studies have examined the clinical effect of
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transporting patients (either with or without first adminis-
tering thrombolytic drugs intravenously) to hospitals where
PCI is performed. A study in Switzerland (n  146) found
similar mortality rates between patients treated at the
presenting hospital (7%) and those treated at a nearby
tertiary-care center (9%) (41). Another series from the
Netherlands (n  165) showed that transporting patients a
short distance (20 miles) could be done safely after the
initial administration of intravenous thrombolytic drugs,
and early angiography with PCI after thrombolysis showed
improved anterograde blood flow in the majority of treated
patients (42). One study (Primary Angioplasty in Patients
Transferred From General Community Hospitals to Spe-
cialized Percutaneous Transluminal Coronary Angioplasty
Units With or Without Emergency Thrombolysis) com-
pared three reperfusion strategies in patients who had AMI
and presented within 6 h of the onset of symptoms at
community hospitals without a catheterization laboratory:
1) immediate thrombolytic therapy (n  99); 2) thrombo-
lytic therapy during transport for immediate angiography
and, as appropriate, angioplasty (n  100); and 3) imme-
diate transport for primary angioplasty without pretreat-
ment with thrombolysis (n  101). The combined primary
end point (death, reinfarction or stroke within 30 days) was
reached less frequently in the third group of patients (8%)
than in the first group (23%) or the second group (15%)
(p 0.02). Transferring patients from community hospitals
to an angioplasty center during the acute phase of MI has
been shown to be safe in this study (43). In contrast, the
AIR-PAMI study compared the outcomes of 71 patients
who were transferred for PCI with the outcomes of 500
patients enrolled in the PAMI No-Surgery-On-Site regis-
try. There was a trend toward higher 30-day mortality for
the transferred patients (8.7% vs. 4.2%, p  0.13), and
one-year mortality was significantly higher in transferred
patients (14.8% vs. 6.1%, p  0.01) (44).
Despite the finding from these studies that patients who
are transferred for primary PCI have outcomes superior to
those who immediately receive thrombolytic therapy, the
data also suggest that patients have an increased frequency
of adverse outcomes if reperfusion therapy is delayed. The
interval from presentation to an emergency department to
performance of PCI (the so-called “door-to-balloon” time)
has been shown to be an important correlate of outcome in
primary angioplasty. In the Global Use of Strategies To
Open occluded arteries (GUSTO-IIb) study, the time from
enrollment to first balloon inflation was an independent
predictor of 30-day mortality (37). Similarly, in the second
NRMI registry, a door-to-balloon time of more than 120
min increased the adjusted odds rate for mortality by 41% to
62% (38). Transporting patients with AMI to a facility
where PCI can be performed probably not only worsens
outcomes, but also increases costs and introduces an addi-
tional emotional burden for patients and their families, who
generally prefer the continuity of care in their community
hospital.
Therefore, the ability to offer prompt primary PCI at the
center to which the patient initially presents is appealing.
The question of whether PCI conducted at centers without
cardiac surgical services is equivalent to PCI performed at
centers that do offer such services must be addressed. Even
more germane is the question of whether it is superior to the
rapid administration of a thrombolytic agent or to the rapid
transfer of patients with AMI who are at high risk or
ineligible for thrombolysis to an institution with cardiac
surgical capabilities.
Studies of primary angioplasty in facilities without on-
site surgery. Relatively few prospective studies have evalu-
ated the outcomes after primary PCI at centers without
on-site cardiac surgery. Several observational series and a
single randomized trial have directly addressed the issue
(45–53) (Tables 2 and 3).
Wharton et al. (48) reported on patients undergoing
primary PCI at two community hospitals without on-site
cardiac surgery. High-risk patients, including those in
cardiogenic shock, and survivors of an out-of-hospital car-
diac arrest were included. The procedural success rate was
94.3%. Angioplasty was not performed in 33.8% of the
patients undergoing immediate angiography for suspected
AMI, because Thrombolysis In Myocardial Infarction
(TIMI) flow grade 3 was present (25.9%), the culprit lesion
was technically unsuitable (6.1%) or the infarct-related
artery could not be identified (1.8%). Among patients in
whom PCI was performed, the median time from arrival in
the emergency department to reperfusion was 102 min,
which is comparable to the corresponding times in random-
ized trials of PCI versus thrombolytic therapy in which
on-site surgery was available. The in-hospital mortality rate
for patients undergoing PCI was 5.3%, and no patient
required emergency CABG from a procedural complication.
In the PAMI No-Surgery-On-Site registry, in which 500
patients were analyzed, procedural success was achieved in
97% of the patients, and TIMI flow grade 3 was restored in
94.2% of the patients. No patient had a reinfarction, and the
in-hospital mortality rate was only 2.8% (46). In the MITI
registry of AMI, 233 of 441 patients had primary angio-
plasty performed at hospitals that did not have on-site
cardiac surgery (49). The procedural success rate in these
patients was 88%, and the in-hospital mortality rate was
5.6%.
We have previously reported the Mayo Clinic’s experi-
ence with primary PCI without cardiac surgery (50). All
components of the primary PCI program at the Mayo
Clinic, Rochester, Minnesota, where on-site cardiac surgery
can be performed, were replicated at a Mayo Health System
hospital without on-site cardiac surgery. In addition, a
telemedicine system to enable real-time consultation with
interventional and cardiac surgical specialists during the
procedure is available. Adhering to a strict patient-selection
protocol, 50 emergency PCIs (ST-segment elevation AMI
or non–ST-segment elevation AMI with ongoing chest
pain) have been performed. Procedural success was achieved
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in 47 patients (94%); there were 2 in-hospital deaths (4%).
No patient required emergency CABG. There were no
additional deaths at 30-day follow-up, and none had rein-
farction or required repeat target vessel revascularization.
In these studies of PCI at centers without cardiac surgery
on-site, the CABG rates during the index hospital period
were 5.3% to 7.0%. These rates were not different from the
6.1% rate of cardiac surgery during the index hospital
admission in the PAMI-STENT trial at a center with
on-site cardiac surgery. In summary, these observational
studies demonstrate the safety and efficacy of primary PCI
in selected community hospitals without on-site cardiac
surgery.
A single, randomized trial directly addressed whether
thrombolytic therapy or primary PCI is preferred at hospi-
tals without on-site surgical capabilities. In the Atlantic
Cardiovascular Patient Outcomes Research Team trial,
which included 11 hospitals where more than one procedure
was performed per month, 453 patients with ST-segment
elevation or left bundle branch block were randomly as-
signed to receive either immediate thrombolytic therapy (n
 227) or angiography and PCI if they had suitable
coronary anatomic indications (n  226) (47). Intracoro-
nary stents and glycoprotein IIb/IIIa inhibitors were used in
70% and 75% of the patients, respectively. In the PCI arm,
the procedural success rate was 91%. The in-hospital mor-
tality was statistically similar between patients undergoing
primary PCI and those receiving thrombolysis (5.5% vs.
7.4%). There was no statistical difference in the individual
end points of recurrent MI (5.2% vs. 6.3%) or stroke (1.3%
vs. 3.5%). However, the composite end point (death, rein-
farction or stroke) occurred in 25.4% of patients receiving
thrombolytic therapy, as compared with 15.4% in the
primary PCI group (relative risk [RR] reduction 42%, p 
0.03). The patients who benefited the most in this trial were
women, those with diabetes mellitus and the elderly. No
patient undergoing PCI required emergency CABG. The
results of this study favor primary PCI, and although they
require confirmation and should be viewed with caution, the
data support the safety and efficacy of primary PCI at
selected sites without on-site cardiac surgery.
Outcome for patients treated with the intention that they
would receive primary angioplasty, but who did not
receive it. Berger et al. (37) demonstrated a relationship
between a delay in performing primary PCI and an early
clinical outcome in the GUSTO-IIb data base. Mortality
within 30 days was lowest among patients treated within 30
days of enrollment and was progressively higher among
patients with a greater delay between enrollment and
balloon inflation. The mortality among 93 patients assigned
to angioplasty who never underwent the procedure was
highest (14.1%). Angioplasty was not performed for the
following reasons: 5 patients died within 2 h before angio-
plasty could be performed; 6 had left main coronary artery
disease of more than 50% and were referred for bypass
surgery; 10 had severe multivessel disease and were referredTa
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for bypass surgery; 3 underwent immediate bypass surgery
for anatomic reasons related to the infarct artery; 1 had
severe mitral regurgitation that required surgery; and 36 had
an infarct-related artery with 70% stenosis or TIMI flow
grade 3, or both. For 32 patients, the exact reasons that
angioplasty was not performed remain unknown.
Indications for emergency CABG. There are two groups
of indications for emergency CABG after AMI: 1) docu-
mentation of severe disease not suitable for PCI; and 2) a
failed coronary intervention requiring emergency CABG.
DOCUMENTATION OF SEVERE DISEASE NOT SUITABLE FOR
PCI. Severe disease includes: 1) an infarct-related artery not
suitable for treatment with PCI because of substantial
myocardial jeopardy; 2) a left main coronary artery lesion
that precludes PCI or complex triple-vessel disease in which
an infarct-related artery cannot be reliably identified; or 3)
mechanical complications such as mitral regurgitation, free
wall rupture or ventricular septal defect.
FAILED CORONARY INTERVENTION REQUIRING EMER-
GENCY CABG. The complications of PCI that can lead to
emergency surgery are: 1) dissection; 2) abrupt closure of the
infarct-related artery; 3) occlusion of the large side branch
during the procedure, with an inability to restore patency
percutaneously; and 4) coronary artery perforation.
In recent years, there has been a steady decline in the
frequency of dissections and abrupt closures. The explana-
tions are multifactorial, but the use of coronary artery stents
has been the most important factor (54). Glycoprotein
IIb/IIIa receptor inhibitors also reduce the need for emer-
gency CABG in patients undergoing PCI (55). In an
analysis of pooled data from two trials (Evaluation of
Platelet IIb/IIIa Inhibitor for Stenting and Evaluation of
Percutaneous Transluminal Coronary Angioplasty to Im-
prove Long-term Outcome With Abciximab Glycoprotein
IIb/IIIa Blockade), the incidence of cardiac surgical proce-
dures was 1.28% in patients receiving abciximab, which is
substantially lower than the incidence of 2.17% in the
placebo group (RR reduction 41%, p  0.021) (55).
Coronary perforations, particularly if they are severe or
occur in patients treated with glycoprotein IIb/IIIa inhibi-
tors, may not respond to prolonged balloon inflation or
pericardiocentesis and may require emergency CABG, but
this complication is rare (56). The recent approval of a
coronary stent covered with a polytetrafluoroethylene mem-
brane should reduce the need for CABG in such cases (57).
Limitations of expanding primary angioplasty to centers
without on-site bypass surgery. There are still many
important factors to consider before primary PCI can be
recommended in community hospitals without on-site sur-
gical capabilities. More than 800 hospitals in the U.S. have
diagnostic catheterization available without on-site cardiac
surgery. In the second NRMI, 25.2% of 1,506 participating
hospitals were capable of performing cardiac catheteriza-
tion, and only 39.2% of the hospitals offered on-site cardiac
surgery (Fig. 1) (20).
Operator competency is an important issue. There is
clearly an association between institutional and individual
procedural volumes and clinical outcome, including mortal-
ity (58,59). In a recent analysis of the second and third
NRMIs, comprising 62,299 patients with AMI, mortality
was lower among patients who received primary PCI than
among those who received thrombolysis at hospitals with
intermediate PCI volumes (i.e., 17 to 48 primary PCI
procedures performed annually) (4.5% vs. 5.9%, p  0.001)
or high volumes (49 primary PCI procedures annually)
(3.4% vs. 5.4%, p  0.001) (60). At low-volume hospitals
(16 primary PCI procedures annually), the mortality was
similar between patients treated with primary PCI and
those treated with thrombolysis (6.2% vs. 5.9%, p  0.58).
A recent study from the 1995 New York State Coronary
Table 3. Studies on Primary Angioplasty in Acute Myocardial Infarction at Sites Without On-Site Cardiac Surgery: Results of PCI
Study (Reference) n
Procedural
Success
TIMI Flow
Grade 3
In-Hospital
Mortality
Repeat
Myocardial
Infarction Stroke
CABG for
Failed
PCI
CABG During
Index Hospital
Admission MACE
Recurrent
PCI
Wharton et al. (48) 506 94.3% 94.3% 6.6% 2.5% 0.4% 0 5.3% 8.2% 3.3%
Weaver et al. (49) 233 88% 88%* 5.6% — 0.6% 0.4% — — —
Johnston et al. (46) 500 97% 94.2% 2.8% 0 0.4% 0.4% 6.3% 3.3% —
Smyth et al. (51) 71 88.7% 88.7% 9.8% 5.6% 0 0 2.8% — 5.6%
Iannone et al. (45) 100 82% — 5.0% — — 7.0% — — —
Brush et al. (52) 62 96% 85% 3.0% 0 0 0 4.0% 5.0% 1.0%
*TIMI flow grade 2/3. Data are presented as the number or percentage of patients.
MACE  major adverse cardiac event; TIMI  Thrombolysis In Myocardial Infarction trial. Other abbreviations as in Table 1.
Figure 1. Most of the 1,506 hospitals in the National Registry of
Myocardial Infarction-2 had the capability to perform coronary angiogra-
phy (Cath-capable), angioplasty (PTCA-capable) or bypass surgery
(CABG-capable). CABG  coronary artery bypass graft surgery; PTCA
 percutaneous transluminal coronary angioplasty. (From Rogers et al.
[20], by permission of the American College of Cardiology.)
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Angioplasty Reporting System Registry analyzed the rela-
tionship between the number of primary angioplasty proce-
dures performed by physicians in hospitals and in-hospital
mortality. Patients who underwent angioplasty procedures
within 23 h after the onset of AMI without preceding
thrombolytic therapy were included (n  1,342). In-
hospital mortality was reduced by 57% among patients who
underwent primary angioplasty performed by high-volume
physicians rather than low-volume physicians (adjusted RR
0.43, 95% confidence interval [CI] 0.21 to 0.83). When
patients with AMI were treated with primary angioplasty in
high-volume hospitals rather than low-volume institutions,
the RR reduction for in-hospital mortality was 44% (adjust-
ed RR 0.56, 95% CI 0.29 to 1.1). Compared with patients
treated at low-volume hospitals by low-volume physicians,
patients treated at high-volume hospitals by high-volume
physicians had a 49% reduction in the risk of in-hospital
mortality (adjusted RR 0.51, 95% CI 0.26 to 0.99) (61).
Thus, all these studies suggest a distinct volume-outcome
relationship for patients undergoing primary PCI.
The successful performance of primary PCI requires an
integrated approach involving physicians, allied health staff
and the logistic constraints of the institution. At some
centers, a strategy of prompt thrombolytic therapy in the
emergency department may be preferable to the adoption of
a policy of primary PCI without on-site cardiac surgery.
Most likely, the ability to perform primary PCI rapidly and
effectively in community hospitals without on-site surgery
would be highly variable. A prerequisite for embarking on
such a policy should be the development of systems that
address the logistic issues, which vary among institutions.
Another requirement for the performance of primary PCI
without on-site cardiac surgery should be the continuous
analysis of all aspects of such a program, including the time
to treatment and clinical and procedural outcomes. The
recent ACC/AHA guidelines recommend essential compo-
nents of a successful program of PCI at a hospital without
on-site cardiac surgical services (6) (Tables 4 and 5).
Conclusions. Primary PCI in qualified community hospi-
tals without on-site cardiac surgery appears to be safe and
effective and may be the best reperfusion therapy. However,
it is unknown to what extent this will be a practical and
effective approach for the majority of community hospitals
in the U.S. and abroad. This area of intervention provides a
great opportunity for evidence-based medicine and transla-
tional research to determine which method of reperfusion is
best suited for a particular institution.
Reprint requests and correspondence: Dr. Bernard J. Gersh,
Division of Cardiovascular Diseases and Internal Medicine, Mayo
Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Table 4. Criteria for the Performance of Angioplasty at
Hospitals Without On-Site Cardiac Surgery
1. The operators must be experienced interventionalists who regularly
perform elective interventions at a surgical center (75 cases/year).
The institution must perform a minimum of 36 primary PCI
procedures per year.
2. The nursing and technical catheterization laboratory staff must be
experienced in handling acutely ill patients and be comfortable with
interventional equipment. They must have acquired experience in
dedicated interventional laboratories at a surgical center. They must
participate in a 24-h, 365-day call schedule.
3. The catheterization laboratory must be well equipped, with optimal
imaging systems, resuscitative equipment, IABP support and a
broad array of interventional equipment.
4. The cardiac care unit nurses must be adept in hemodynamic
monitoring and IABP management.
5. The hospital administration must fully support the program and
enable the fulfillment of the aforementioned institutional
requirements.
6. There must be formalized written protocols in place for immediate
(within 1 h) and efficient transfer of patients to the nearest cardiac
surgical facility, and these protocols should be reviewed and tested
on a regular (quarterly) basis.
7. Primary intervention must be performed routinely as the treatment
of choice around the clock for a large proportion of patients with
acute myocardial infarction to ensure streamlined care paths and
increased case volumes.
8. Case selection for the performance of primary angioplasty must be
rigorous. Criteria for the types of lesions appropriate for primary
angioplasty and for the selection of patients in need of transfer for
emergency aortocoronary bypass surgery are shown in Table 5.
9. There must be an ongoing program of outcomes analysis and
formalized periodic case review.
10. Institutions should participate in a 3- to 6-month period of
implementation, during which time the development of a formalized
primary PCI program is instituted that includes establishing
standards, training staff, developing detailed logistics and creating a
quality assessment and error management system.
From Smith et al. (6), by permission of the American College of Cardiology and
American Heart Association.
IABP  intra-aortic balloon pump; PCI  percutaneous coronary intervention.
Table 5. Patient Selection for Angioplasty and Emergency
Aortocoronary Bypass at Hospitals Without On-Site
Cardiac Surgery
Avoid intervention in hemodynamically stable patients with:
Significant stenosis (60%) of an unprotected left main coronary
artery upstream from an acute occlusion in the left coronary
system, which might be disrupted by the angioplasty catheter
Extremely long or angulated infarct-related lesions with TIMI flow
grade 3
Infarct-related lesions with TIMI flow grade 3 in patients in a stable
condition with triple-vessel disease
Infarct-related lesions of small or secondary vessels
Lesions in other than the infarct-related artery
Transfer for emergency aortocoronary bypass surgery of those patients
who have:
High-grade residual left main or multivessel coronary artery disease
and clinical or hemodynamic instability (after angioplasty of
occluded vessels and preferably with intra-aortic balloon pump
support)
From Smith et al. (6), by permission of the American College of Cardiology and
American Heart Association.
TIMI  Thrombolysis In Myocardial Infarction.
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